\begin{tabular}{lccccccccc}
   \hline
 
         \multicolumn{1}{l}{Mock} & \multicolumn{1}{c}{Tertile}   & \multicolumn{1}{c}{No. cases /}   & \multicolumn{1}{c}{Attack}   & \multicolumn{2}{c}{Haz. Ratio}                     & \multicolumn{1}{c}{P-value}   & \multicolumn{1}{c}{Overall P-}      & \multicolumn{1}{c}{Overall q-}   & \multicolumn{1}{c}{Overall} \\ 
         \multicolumn{1}{l}{Immunologic Marker}            & \multicolumn{1}{c}{}          & \multicolumn{1}{c}{No. at-risk**} & \multicolumn{1}{c}{rate}   & \multicolumn{1}{c}{Pt. Est.} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{(2-sided)} & \multicolumn{1}{c}{value***} & \multicolumn{1}{c}{value} & \multicolumn{1}{c}{FWER} \\ 
         \hline
 
    Spike IgG & Lower & 66/4,430 & 0.0149 & 1 & N/A & N/A & $<$0.001 & $<$0.001 & $<$0.001 \\ 
  (IU/ml) & Middle & 4/4,412 & 0.0009 & 0.05 & (0.02-0.15) & $<$0.001 &     &     &     \\ 
   & Upper & 1/4,456 & 0.0002 & 0.01 & (0.00-0.04) & $<$0.001 &     &     &     \\ 
  RBD IgG & Lower & 47/4,430 & 0.0106 & 1 & N/A & N/A & $<$0.001 & $<$0.001 & $<$0.001 \\ 
  (IU/ml) & Middle & 17/4,432 & 0.0038 & 0.34 & (0.19-0.62) & $<$0.001 &     &     &     \\ 
   & Upper & 7/4,435 & 0.0016 & 0.05 & (0.02-0.12) & $<$0.001 &     &     &     \\ 
  PsV-nAb & Lower & 48/4,424 & 0.0108 & 1 & N/A & N/A & $<$0.001 & $<$0.001 & $<$0.001 \\ 
  ID50 & Middle & 16/4,440 & 0.0036 & 0.23 & (0.12-0.42) & $<$0.001 &     &     &     \\ 
   & Upper & 7/4,433 & 0.0016 & 0.07 & (0.03-0.16) & $<$0.001 &     &     &     \\ 
  PsV-nAb & Lower & 57/4,431 & 0.0129 & 1 & N/A & N/A & $<$0.001 & $<$0.001 & $<$0.001 \\ 
  ID80 & Middle & 11/4,426 & 0.0025 & 0.17 & (0.09-0.34) & $<$0.001 &     &     &     \\ 
   & Upper & 3/4,440 & 0.0007 & 0.03 & (0.01-0.08) & $<$0.001 &     &     &     \\ 
    
 \multicolumn{8}{l}{} \\ 

 \multicolumn{2}{l}{Placebo} & 710/13,326&0.0533&\multicolumn{4}{l}{}  \\ 
 \hline
\end{tabular}
